CN106109564A - Pharmaceutical composition for the treatment of cerebral thrombosis and preparation method thereof - Google Patents
Pharmaceutical composition for the treatment of cerebral thrombosis and preparation method thereof Download PDFInfo
- Publication number
- CN106109564A CN106109564A CN201610515685.2A CN201610515685A CN106109564A CN 106109564 A CN106109564 A CN 106109564A CN 201610515685 A CN201610515685 A CN 201610515685A CN 106109564 A CN106109564 A CN 106109564A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- ethanol
- cerebral thrombosis
- percent concentration
- weight percent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 59
- 201000001429 Intracranial Thrombosis Diseases 0.000 title claims abstract description 45
- 206010008132 Cerebral thrombosis Diseases 0.000 title claims abstract description 43
- 238000011282 treatment Methods 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 53
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 claims abstract description 52
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 claims abstract description 44
- 229940079593 drug Drugs 0.000 claims abstract description 36
- GTRPODKMSBFDOI-UHFFFAOYSA-N Protopine Natural products CN1Cc2c3OCOc3ccc2C4C1Cc5cc6OCOc6cc5C4=O GTRPODKMSBFDOI-UHFFFAOYSA-N 0.000 claims abstract description 26
- ZAALQOFZFANFTF-UHFFFAOYSA-N Pseudoprotipine Natural products C1=C2C(=O)CC3=CC=4OCOC=4C=C3CN(C)CCC2=CC2=C1OCO2 ZAALQOFZFANFTF-UHFFFAOYSA-N 0.000 claims abstract description 26
- CHWPMFMUQATVNK-ARYYTZDLSA-N dihydrosporogen AO-1 Natural products O[C@H]1[C@]2(C(C)=C)O[C@@H]2[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1 CHWPMFMUQATVNK-ARYYTZDLSA-N 0.000 claims abstract description 26
- 239000000460 chlorine Substances 0.000 claims abstract description 23
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 23
- 235000007336 cyanidin Nutrition 0.000 claims abstract description 22
- 241000238659 Blatta Species 0.000 claims abstract description 20
- 240000009005 Calendula arvensis Species 0.000 claims abstract description 20
- 235000007864 Calendula arvensis Nutrition 0.000 claims abstract description 20
- 241000238661 Periplaneta Species 0.000 claims abstract description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 140
- 239000000284 extract Substances 0.000 claims description 40
- 239000011347 resin Substances 0.000 claims description 29
- 229920005989 resin Polymers 0.000 claims description 29
- 230000000274 adsorptive effect Effects 0.000 claims description 28
- 238000000605 extraction Methods 0.000 claims description 28
- 239000002904 solvent Substances 0.000 claims description 28
- 239000007788 liquid Substances 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 22
- 238000010828 elution Methods 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000012141 concentrate Substances 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 8
- 239000006187 pill Substances 0.000 claims description 8
- 230000002879 macerating effect Effects 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 241000254173 Coleoptera Species 0.000 claims description 3
- 241000231739 Rutilus rutilus Species 0.000 claims description 3
- 238000007796 conventional method Methods 0.000 claims description 3
- 210000003608 fece Anatomy 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 25
- 230000003727 cerebral blood flow Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229940093181 glucose injection Drugs 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- QELDJEKNFOQJOY-ZDUSSCGKSA-N Isocorydine Chemical compound CN1CCC2=CC(OC)=C(OC)C3=C2[C@@H]1CC1=CC=C(OC)C(O)=C13 QELDJEKNFOQJOY-ZDUSSCGKSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960001284 citicoline Drugs 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 229940090044 injection Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- DRVVGOFZCWCCSA-UHFFFAOYSA-N isocorydine Natural products COc1cc2CCN(C)C3Cc4cccc(C)c4c(c1O)c23 DRVVGOFZCWCCSA-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000008155 medical solution Substances 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 206010048946 Anal abscess Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000133570 Berberidaceae Species 0.000 description 1
- 241000238660 Blattidae Species 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 241000873224 Capparaceae Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241001116782 Cleome Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- DEOAEBOOLNZVLW-UHFFFAOYSA-N Linichlorin A Natural products CC=C/C(=O)OC1CC(=C)C2CC(O)C(O)(CCl)C2C3OC(=O)C(=C)C13 DEOAEBOOLNZVLW-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000007695 Nandina domestica Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000904014 Pappus Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241000238675 Periplaneta americana Species 0.000 description 1
- 241001510004 Periplaneta australasiae Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 240000007643 Phytolacca americana Species 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 235000002560 Solanum lycopersicum Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000219175 Thalictrum przewalskii Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 241001403962 Thymus mongolicus Species 0.000 description 1
- 240000006001 Thymus serpyllum Species 0.000 description 1
- 235000004054 Thymus serpyllum Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008862 fructus schizandrae, radix ginseng, radix ophiopogonis drug combination Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 230000004895 regional blood flow Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 230000003238 somatosensory effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000023409 throat pain Diseases 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960003232 troxerutin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition treating cerebral thrombosis and preparation method thereof, pharmaceutical composition of the present invention is with Calendula arvensis L., Herba thymi vulgaris, Fructus Nandinae Domesticae, smelly arrow dish, Blatta seu periplaneta, protopine, 19 deoxidation 15 chlorine Jia Shi cyanidin as crude drug, proportioning forms, can make various dosage form by preparation process routinely, treatment cerebral thrombosis is evident in efficacy.
Description
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to a kind of pharmaceutical composition treating cerebral thrombosis and preparation side thereof
Method.
Background technology
Cerebral thrombosis is the modal type of cerebral infarction.It is cerebral arteries trunk or cortical branches atherosclerosis causes blood
Pipe thickens, luminal stenosis inaccessible and thrombosis, causes brain regional blood flow to reduce or blood supply is interrupted, and brain tissue ischemia anoxia causes
Soften necrosis and focal neurological symptom occurs.Heilungkiang News Network interrogates in recent years, suffers from people's age of cerebral thrombosis constantly
Reducing, within about 40 years old, occur the patient of cerebral infarction the rarest, the most common, what cerebral thrombus patient became younger becomes
Gesture is the most serious.A few days ago, reporter recognizes breathing out the medical university forth academy, because cerebral infarction connects to have in subject patient in hospital 1/3rd is
The person between twenty and fifty of about 40 years old.According to three head of the department's professor's Zhang Zhuobai introductions in the Kazakhstan forth academy of medical university nerve, nearly ten years, clinic finds
The cerebral infarction patient of the right side of fifty added two one-tenth than in the past, and the prevalence at such low age is the rarest in the past.Cause
Main cause of its morbidity is irregular, unhealthy with the diet of people and is in that stress is big, fatigue state is relevant for a long time.Doctor
Raw prompting, in daily life, it should be noted that regulation emotion, keeps appropriate motion, eats the food high containing cholesterol less, such as egg
Huang, pluck, seafood etc..--> (Heilungkiang News Network-Heilungkiang daily paper)
The sickness rate of cerebral thrombosis still has the trend of rising in recent years, also should be increasingly by the concern of people.Treat brain at present
The conventional medicine of thrombosis have low molecular dextran, nicotinic acid, papaverine, troxerutin, compound recipe pellet energy injection, ligustrazine,
Antithrombotic pill, Senc etc..Though these medicines have certain curative effect but the most of great satisfaction.
Calendula arvensis L.: for herb and the flower of the little Flos Inulae of feverfew.Summer gathers.[original shape state] annual or biennial grass
This, high 40 cm, the scattered pubescence of Herb.Stem is upright, and branch is arranged at top.Single leaf alternate；Long elliptic-lanceolate, tip is gradually
Point, edge tool rough sawn tooth, base portion wedge shape.Head inflorescence top is raw, has stalk, diameter 2 cm；Phyllary is green, linear, edge
Film quality；Edge ligulate flower, female, sulfur color, tongue piece tip 3 tooth；Central tubular flower both sexes, tip 5 splits；Holder is smooth, without torr
Sheet.Achene, back has soft thorn, and outermost columns has mouth shape directly to give birth to, and interior columns introversion is the most ring-type, without pappus.Summer at florescence.
There is cultivation in [habitat branch] flower garden, China various places more.[chemical composition] flower is containing quintessence oil, amaroid, resin, natural gum.[function cures mainly]
1. " modern Practical Chinese medicinal ": " diuresis, diaphoresis, excited, laxation, stimulates the menstrual flow.Control again perianal abscess hematochezia more than." 2. " name planted by Guangxi medicine
Record ": " blood pressure lowering." [extracts] " Chinese medicine voluminous dictionary ".
Herba thymi vulgaris: for Labiatae Thymus plant Herba thymi vulgaris Thymus serpyllum L. [T. mongolicus
Ronn.] and Herba Thymi (thymus przewalskiiNakai) T. przewalskii (Komar.) Nakai, with all herbal medicine.Summer, branch and leaf were luxuriant
Shi Caishou, pulls up Herb, cleans, cuts off root (being available for Lycopersicum esculentum), cutting, using fresh herb or dry.[nature and flavor] are pungent, tepor.[merit
Can cure mainly] expelling pathogenic wind from the body surface, promoting the circulation of QI to relieve pain, cough-relieving, blood pressure lowering.For catching a cold, cough, headache, toothache, dyspepsia, acute gastrointestinal
Inflammation, hypertension.[extracts] " whole nation Chinese herbal medicine compilation ".
Fructus Nandinae Domesticae: for the fruit of Berberidaceae plant Fructus Nandinae Domesticae Nandina domestica Thunb..Fruit is in 11～12
Month or gather February, dry.[original shape state] evergreen shrubs, high about 2m.Stem is upright, sprout yellow.Leaf alternate, the raw stem end of collection, is three
Returning winglike compound leaf, lobule keratin, ellipticity lanceolar, length 3～7cm, tip is tapering, Quan Yuan, bottle green, and often redden winter color；
Below lobule and petiole base has joint.Panicle top is raw；Tapel is taken turns more, often 3, wheel, and foreign steamer is little, inside takes turns big；Stamen 6,
Petal-shaped；Ovary is upper.Berry is spherical, cerise time ripe.Florescence 5～June, really phase 9～October.[character] fruit is spherical, directly
Footpath 7～9mm.Surface yellowish red color or reddish violet, smooth, micro-tool gloss, the most slightly concave sunken, top harbors the base for post of micro-protuberance, base
There are thin fruit stem or its mark of break in portion.Peel matter is crisp frangible, and two, seed, the most hemispherical, inner face is recessed, yellowish-brown.Sour-puckery flavor.
[chemical composition] contains isocorydine (isocorydine), protopine (protopine), 0-methyl 1-hydroxy-2-methoxy-9,10-methylenedioxyaporphine. (0-
Methyldomesticine), hydrocyanic acid etc..[nature and flavor] property is put down, sour in the mouth, sweet.[function cures mainly] astringes the lung antitussive.For chronic cough gas
Breathe heavily, pertussis.[extracts] " Chinese medicine voluminous dictionary ".
Smelly arrow dish: Capparidaceae smelly arrow dish Cleome vircosa L., with all herbal medicine.[habitat branch] Fujian, platform
Gulf, Jiangxi, Hunan, Guangdong, Guangxi, Yunnan.[nature and flavor] are bitter, pungent, temperature.Poisonous.[function cures mainly] dissipating blood stasis for subsidence of swelling, removing the necrotic tissue and promoting granulation.
[extracts] " whole nation Chinese herbal medicine compilation ".
Blatta seu periplaneta: Blattidae insecticide Australian cockroach Periplaneta australasie Fabricius or american cockroach
(big cockroach) P. americana L., is used as medicine with dry polypide.The four seasons can catch, and boiled water scalds dead, dries or dries.[nature and flavor]
Salty, cold.Slightly poisonous.[function cures mainly] dissipating blood stasis disappears knot, diuresis of detoxifying.For throat pain, tonsillitis, infantile malnutrition, liver cirrhosis
Ascites, dysuria；Snake bite and insect sting, ulcerative carbuncle toxic swelling, tinea pedis edema, asthma, stranguria with turbid discharge are controlled in external.[extracts] " whole nation medium-height grass
Medicine collects ".
Protopine (Protopine): molecular formula: C20H19NO5,Molecular weight: 353.37, CAS accession number: 130-
86-9。
19-deoxidation-15-chlorine Jia Shi cyanidin (19-Deoxy-15-Chlorojanerin): molecular formula:
C19H23ClO6Molecular weight: 382.84, CAS accession number: 62462-98-0. density: 1.336g/cm3Boiling point:
552.321 ° of C at 760 mmHg. flash-points: 287.833 ° of C.
Summary of the invention
It is an object of the invention to overcome the deficiency of background technology, it is provided that the pharmaceutical composition of a kind of effective treatment cerebral thrombosis and
Its preparation method.
The present invention adopts the following technical scheme that realization:
Composition and the weight portion of making the crude drug of the pharmaceutical composition of this treatment cerebral thrombosis be:
Calendula arvensis L. 650 750g, Herba thymi vulgaris 2450 2550g, Fructus Nandinae Domesticae 2650 2750g, smelly arrow dish 3250 3350g, roach
Dung beetle 4650 4750g, protopine 102 112g, 19-deoxidation-15-chlorine Jia Shi cyanidin 93 103g.
It is preferably used in the pharmaceutical composition for the treatment of cerebral thrombosis, is made up of the crude drug of following weight portion:
Calendula arvensis L. 700g, Herba thymi vulgaris 2500g, Fructus Nandinae Domesticae 2700g, smelly arrow dish 3300g, Blatta seu periplaneta 4700g, protopine 107g, 19-
Deoxidation-15-chlorine Jia Shi cyanidin 98g.
A kind of pharmaceutical composition treating cerebral thrombosis, it is characterised in that pharmaceutical composition can use the routine side of galenic pharmacy
Method prepares piece agent or capsule or drop pill.
A kind of pharmaceutical composition treating cerebral thrombosis, it is characterised in that pharmaceutical composition and controlling that chemical drugs or Chinese medicine form
Treat cerebral thrombosis medicine.
The preparation method of a kind of pharmaceutical composition treating cerebral thrombosis, it is characterised in that prepare as follows:
The composition of crude drug and weight portion be: Calendula arvensis L. 650 750g, Herba thymi vulgaris 2450 2550g, Fructus Nandinae Domesticae 2650
2750g, smelly arrow dish 3250 3350g, Blatta seu periplaneta 4650 4750g, protopine 102 112g, 19-deoxidation-15-chlorine Jia Shi vow
Car centautin 93 103g；
Preparation method:
(1) Calendula arvensis L., Herba thymi vulgaris, Fructus Nandinae Domesticae, smelly arrow dish, Blatta seu periplaneta, protopine, 19-deoxidation-15-chlorine are taken by crude drug proportioning
Jia Shi cyanidin, mixing, with weight percent concentration 46.5% ethanol as solvent, extract at 57 DEG C of warm macerating, extraction time is
8 times, each extraction time is 30 hours, and each solvent load is 45 times of crude drug gross weight, filters, obtains medicinal residues A and extraction
Liquid A, extracting solution A reclaim ethanol, are concentrated into relative density 1.12, filter, and medicinal liquid passes through LSA-40 macroporous adsorptive resins, first uses
Water elution, then with weight percent concentration 63% ethanol solution eluting LSA-40 macroporous adsorptive resins, collect percentage by weight dense
Spend 63% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A；
(2) take step (1) medicinal residues A, with weight percent concentration 41% ethanol as solvent, heating and refluxing extraction 11 times, carry every time
The time of taking is 1.5 hours, and each solvent load is 15 times of medicinal residues A weight, filters, obtains medicinal residues B and extracting solution B, and extracting solution B returns
Receiving ethanol, be concentrated into relative density 1.14, filter, medicinal liquid passes through DM11 macroporous adsorptive resins, first washes with water, then uses weight
Percent concentration 64% ethanol solution eluting DM11 macroporous adsorptive resins, collects weight percent concentration 64% ethanol elution,
Reclaim ethanol, concentrate drying, obtain extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
The preparation method of a kind of pharmaceutical composition treating cerebral thrombosis, it is characterised in that prepare as follows:
The composition of crude drug and weight portion be: Calendula arvensis L. 700g, Herba thymi vulgaris 2500g, Fructus Nandinae Domesticae 2700g, smelly arrow dish 3300g, roach
Dung beetle 4700g, protopine 107g, 19-deoxidation-15-chlorine Jia Shi cyanidin 98g；
Preparation method:
(1) Calendula arvensis L., Herba thymi vulgaris, Fructus Nandinae Domesticae, smelly arrow dish, Blatta seu periplaneta, protopine, 19-deoxidation-15-chlorine are taken by crude drug proportioning
Jia Shi cyanidin, mixing, with weight percent concentration 46.5% ethanol as solvent, extract at 57 DEG C of warm macerating, extraction time is
8 times, each extraction time is 30 hours, and each solvent load is 45 times of crude drug gross weight, filters, obtains medicinal residues A and extraction
Liquid A, extracting solution A reclaim ethanol, are concentrated into relative density 1.12, filter, and medicinal liquid passes through LSA-40 macroporous adsorptive resins, first uses
Water elution, then with weight percent concentration 63% ethanol solution eluting LSA-40 macroporous adsorptive resins, collect percentage by weight dense
Spend 63% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A；
(2) take step (1) medicinal residues A, with weight percent concentration 41% ethanol as solvent, heating and refluxing extraction 11 times, carry every time
The time of taking is 1.5 hours, and each solvent load is 15 times of medicinal residues A weight, filters, obtains medicinal residues B and extracting solution B, and extracting solution B returns
Receiving ethanol, be concentrated into relative density 1.14, filter, medicinal liquid passes through DM11 macroporous adsorptive resins, first washes with water, then uses weight
Percent concentration 64% ethanol solution eluting DM11 macroporous adsorptive resins, collects weight percent concentration 64% ethanol elution,
Reclaim ethanol, concentrate drying, obtain extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
The preparation method of a kind of pharmaceutical composition treating cerebral thrombosis, it is characterised in that pharmaceutical composition can use preparation
The conventional method learned is prepared as tablet or capsule or drop pill.
A kind of preparation method of the pharmaceutical composition treating cerebral thrombosis, it is characterised in that pharmaceutical composition and chemical drugs or in
Medicine composition treatment cerebral thrombosis medicine.
Detailed description of the invention
Embodiment 1: pharmaceutical composition for the treatment of cerebral thrombosis and preparation method thereof
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of cerebral thrombosis be: Calendula arvensis L. 700g, Herba thymi vulgaris 2500g, sky
Zhu Zi 2700g, smelly arrow dish 3300g, Blatta seu periplaneta 4700g, protopine 107g, 19-deoxidation-15-chlorine Jia Shi cyanidin 98g；
Preparation method:
(1) Calendula arvensis L., Herba thymi vulgaris, Fructus Nandinae Domesticae, smelly arrow dish, Blatta seu periplaneta, protopine, 19-deoxidation-15-chlorine are taken by crude drug proportioning
Jia Shi cyanidin, mixing, with weight percent concentration 46.5% ethanol as solvent, extract at 57 DEG C of warm macerating, extraction time is
8 times, each extraction time is 30 hours, and each solvent load is 45 times of crude drug gross weight, filters, obtains medicinal residues A and extraction
Liquid A, extracting solution A reclaim ethanol, are concentrated into relative density 1.12, filter, and medicinal liquid passes through LSA-40 macroporous adsorptive resins, first uses
Water elution, then with weight percent concentration 63% ethanol solution eluting LSA-40 macroporous adsorptive resins, collect percentage by weight dense
Spend 63% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A；
(2) take step (1) medicinal residues A, with weight percent concentration 41% ethanol as solvent, heating and refluxing extraction 11 times, carry every time
The time of taking is 1.5 hours, and each solvent load is 15 times of medicinal residues A weight, filters, obtains medicinal residues B and extracting solution B, and extracting solution B returns
Receiving ethanol, be concentrated into relative density 1.14, filter, medicinal liquid passes through DM11 macroporous adsorptive resins, first washes with water, then uses weight
Percent concentration 64% ethanol solution eluting DM11 macroporous adsorptive resins, collects weight percent concentration 64% ethanol elution,
Reclaim ethanol, concentrate drying, obtain extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
Embodiment 2: pharmaceutical composition for the treatment of cerebral thrombosis and preparation method thereof
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of cerebral thrombosis be: Calendula arvensis L. 650g, Herba thymi vulgaris 2550g, sky
Zhu Zi 2650g, smelly arrow dish 3350g, Blatta seu periplaneta 4650g, protopine 112g, 19-deoxidation-15-chlorine Jia Shi cyanidin 93g；
Preparation method:
(1) Calendula arvensis L., Herba thymi vulgaris, Fructus Nandinae Domesticae, smelly arrow dish, Blatta seu periplaneta, protopine, 19-deoxidation-15-chlorine are taken by crude drug proportioning
Jia Shi cyanidin, mixing, with weight percent concentration 46.5% ethanol as solvent, extract at 57 DEG C of warm macerating, extraction time is
8 times, each extraction time is 30 hours, and each solvent load is 45 times of crude drug gross weight, filters, obtains medicinal residues A and extraction
Liquid A, extracting solution A reclaim ethanol, are concentrated into relative density 1.12, filter, and medicinal liquid passes through LSA-40 macroporous adsorptive resins, first uses
Water elution, then with weight percent concentration 63% ethanol solution eluting LSA-40 macroporous adsorptive resins, collect percentage by weight dense
Spend 63% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A；
(2) take step (1) medicinal residues A, with weight percent concentration 41% ethanol as solvent, heating and refluxing extraction 11 times, carry every time
The time of taking is 1.5 hours, and each solvent load is 15 times of medicinal residues A weight, filters, obtains medicinal residues B and extracting solution B, and extracting solution B returns
Receiving ethanol, be concentrated into relative density 1.14, filter, medicinal liquid passes through DM11 macroporous adsorptive resins, first washes with water, then uses weight
Percent concentration 64% ethanol solution eluting DM11 macroporous adsorptive resins, collects weight percent concentration 64% ethanol elution,
Reclaim ethanol, concentrate drying, obtain extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
Embodiment 3: pharmaceutical composition for the treatment of cerebral thrombosis and preparation method thereof
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of cerebral thrombosis be: Calendula arvensis L. 750g, Herba thymi vulgaris 2450g, sky
Zhu Zi 2750g, smelly arrow dish 3250g, Blatta seu periplaneta 4750g, protopine 102g, 19-deoxidation-15-chlorine Jia Shi cyanidin 103g；
Preparation method:
(1) Calendula arvensis L., Herba thymi vulgaris, Fructus Nandinae Domesticae, smelly arrow dish, Blatta seu periplaneta, protopine, 19-deoxidation-15-chlorine are taken by crude drug proportioning
Jia Shi cyanidin, mixing, with weight percent concentration 46.5% ethanol as solvent, extract at 57 DEG C of warm macerating, extraction time is
8 times, each extraction time is 30 hours, and each solvent load is 45 times of crude drug gross weight, filters, obtains medicinal residues A and extraction
Liquid A, extracting solution A reclaim ethanol, are concentrated into relative density 1.12, filter, and medicinal liquid passes through LSA-40 macroporous adsorptive resins, first uses
Water elution, then with weight percent concentration 63% ethanol solution eluting LSA-40 macroporous adsorptive resins, collect percentage by weight dense
Spend 63% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A；
(2) take step (1) medicinal residues A, with weight percent concentration 41% ethanol as solvent, heating and refluxing extraction 11 times, carry every time
The time of taking is 1.5 hours, and each solvent load is 15 times of medicinal residues A weight, filters, obtains medicinal residues B and extracting solution B, and extracting solution B returns
Receiving ethanol, be concentrated into relative density 1.14, filter, medicinal liquid passes through DM11 macroporous adsorptive resins, first washes with water, then uses weight
Percent concentration 64% ethanol solution eluting DM11 macroporous adsorptive resins, collects weight percent concentration 64% ethanol elution,
Reclaim ethanol, concentrate drying, obtain extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
Embodiment 4: the preparation of tablet
Example 1 pharmaceutical composition 300g, adds starch 110g, mixing, pelletizes, be dried, add microcrystalline Cellulose 35g, stearic
Acid magnesium 3g, mixing, it is pressed into 1000, obtains medicinal composition tablets.
Embodiment 5: the preparation of capsule
Example 2 pharmaceutical composition 302g, adds starch 90g, mixing, pelletizes, be dried, granulate, add appropriate magnesium stearate,
Mixing, obtains medicament composition capsule by encapsulated 1000.
Embodiment 6: the preparation of drop pill
Weigh polyethylene glycol 6000 193g water-bath (80 DEG C) heating and boil molten, add embodiment 3 pharmaceutical composition 14g, fully stir
Mixing uniformly, with liquid paraffin as coolant, put in glass tubing (4*80cm), chilling temperature is 5 DEG C, and drip internal-and external diameter is 7.0/
2.0 (mm/mm), drip is 2.5cm away from liquid level, drips fast with 50 every point as optimum condition, blots the cold of drop pill surface with cotton
Solidifying agent, obtains medicament composition dropping pills.
Embodiment 7: the pharmaceutical composition for the treatment of cerebral thrombosis
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of cerebral thrombosis be:
Fructus Nandinae Domesticae 3050g, Blatta seu periplaneta 4550g, protopine 82g, 19-deoxidation-15-chlorine Jia Shi cyanidin 65g.
Embodiment 8: the pharmaceutical composition for the treatment of cerebral thrombosis
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of cerebral thrombosis be:
Fructus Nandinae Domesticae 3000g, Blatta seu periplaneta 4600g, protopine 72g, 19-deoxidation-15-chlorine Jia Shi cyanidin 75g.
Embodiment 9: the pharmaceutical composition for the treatment of cerebral thrombosis
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of cerebral thrombosis be:
Fructus Nandinae Domesticae 3100g, Blatta seu periplaneta 4500g, protopine 92g, 19-deoxidation-15-chlorine Jia Shi cyanidin 55g.
Experimental example 1: the experimental study for the treatment of cerebral thrombosis
1 data and method
1.1 physical data
Cerebral thrombus patient 100 example choosing Shandong Qilu Hospital's treatment of in November, 2013～in November, 2014 is right as research
As, all inform selected patient and obtain agreement.It is divided at random observation group and each 50 examples of matched group, man 26 in matched group
Example, female 24 example, age 41～73 years old, the mean age is (55.5 ± 6.8) year, complication with diabetes l0 example, complicated hypertension 35 example,
Merge coronary heart disease 5 example；Male 25 examples in observation group, female 25 example, age 40～73 years old, the mean age be (56.3 ± 7.6) year, close
And diabetes l0 example, complicated hypertension 36 example, merge coronary heart disease 4 example.All patients all meet diagnostic criteria and sweep through brain CT
Retouch and make a definite diagnosis, get rid of serious hepatic and kidney function obstacle person.Two groups of aspect comparing difference not statistically significants such as patient age, sex (
0.05), there is comparability.
1 .2 Therapeutic Method
1.2 .1 matched groups use the treatment of low molecular dextran, SHENMAI ZHUSHEYE, citicoline.250～500m low molecule
The admixing medical solutions of dextran glucose injection, 0.5g citicoline and 250m L 5% glucose injection, 40mL joins
Wheat injection and the admixing medical solutions of 250mL 5% glucose injection, intravenous drip, 1 time/d.Glucose is noted by diabetics
Penetrate liquid and replace to normal saline.Oral 50mg enteric coated aspirin sheet, 100mgVitE, 1 time/d, be used in conjunction 3 months.Give simultaneously
The symptomatic treatments such as fall intracranial pressure, blood sugar lowering, blood pressure lowering.
1.2.2 observation group
On the basis of the western medical treatment of matched group, add this pharmaceutical composition (embodiment 1 pharmaceutical composition lot number 20121229)
Treatment, three times a day, each 1.5g, carry out efficacy determination after being used in conjunction March.
1.3 evaluation index
(1) " apoplexy patient neurological deficits score standard " with reference to nineteen ninety-five whole nation cerebrovascular academic conference revision is carried out
Scoring, the slip of two groups of scorings after comparison therapy.Cure: scoring reduces more than 76%, and life is taken care of oneself completely, Return to work hilllock
Position；Effective: scoring reduces 50%～75%, and part life can be taken care of oneself, and can be engaged in simple activities；Effective: scoring subtract 11%～
50%, can live under helping, it is impossible to be engaged in activity；Invalid: scoring reduces less than 10% or increased, and living condition is without changing
Kind, the state of an illness even deteriorates or dead without taking a turn for the better.Total effective rate=(cure+effective+effectively)/total number of cases.(2) two groups of treatments are compared
The change of infarction side cerebral blood flow, flow velocity front and back.
1.4 statistical method
Using SPSSl1.0 statistical software to carry out statistical procedures the data obtained, data are with X ± S) represent, wherein measure
Data uses t inspection, and enumeration data uses X2Inspection, P < 0.05 is statistically significant.
2 results
2.1 liang of group patient clinical therapeutic effect compare
Observation group's total effective rate 94.0%, matched group is 72.0%, and two groups are compared, and has significant difference (P < 0.05), sees
Examine group clinical efficacy apparently higher than matched group.It is shown in Table 1.
1 liang of table group patient clinical therapeutic effect comparative example
| Group | Number of cases | Cure | Effective | Effectively | Invalid | Total effective rate (%) |
| Matched group | 50 | 10 | 13 | 13 | 14 | 72.0 |
| Observation group | 50 | 22 | 17 | 8 | 3 | 94.0 |
Before and after 2.2 liang of group treatments, relatively two groups treatment Cerebral Blood Flow Followings of cerebral blood flow, velocity ratio and cerebral blood flow speed all have increase, see
Examine group treatment after with treatment before compared with, all there were significant differences for cerebral blood flow and cerebral blood flow speed (P < 0.05), after treatment of control group with
Comparing before treatment, cerebral blood flow and cerebral blood flow speed are without significant difference (P > 0.05), the cerebral blood flow after observation group's treatment and brain blood
Flow velocity compared with matched group, difference statistically significant (P < 0.05).It is shown in Table 2.
Before and after the group treatment of 2 liang of table, infarction side cerebral blood flow, velocity ratio are relatively
Result observation group total effective rate is 94.0%, matched group be 72.0%, simultaneously observation group's cerebral blood flow and cerebral blood flow speed also
Apparently higher than matched group.In sum, this pharmaceutical composition (embodiment 1 pharmaceutical composition lot number 20121229) treatment clinic is treated
Effect is notable, is worthy to be popularized.
Experimental example 2, model case
Xiao XX, man, 52 years old, suffer from hypertension for many years, but the most not asymptomatic.He is the people that a self-disciplining is very poor, takes out at ordinary times
Cigarette is severe.Feel to have the pins and needles during in December, 2014, go hospital diagnosis to say slight thrombosis, all right after two weeks the most in hospital
?.Somatosensory is the most fine later.Feeling like jelly until feeling that trick is unable on February 19th, 2015, going to hospital to see is thrombosis shape again
Cheng Liao, had beaten drop at that time, but when late home is lived, and second day as a result morning fell down when going to toilet suddenly, and the state of an illness increases the weight of suddenly.
Left side trick is the most active, the thinking also ratio compared with normal but he speaks, it is impossible to oneself stands up.Start this medicine oral on February 20th, 2015
Compositions (embodiment 1 pharmaceutical composition lot number 20121229) is treated, three times a day, each 1.5g, permissible after serveing on 4 months
Go to ground activity, communication that can be more visible with people, the check of 5 Ge Yuehou hospitals, blood pressure is normal, lives normal, continues clothes afterwards
Thoroughly cured with 2 months.
Thunder XX, man, 54 years old, in evening on October 15th, 2014, unexpected cerebral thrombosis showed effect, unconscious, is sent in a hurry hospital of city,
Rescuing, on inspection, bilateral cerebral blocks, and doctor requires hospitalization at once, but, one is admitted to hospital must hand over 2000 yuan
The cash pledge of money, owing to being poorly off, cannot take out the most money, so, beat transfusion bottle and just gone home.The when of 7th day, always
Other just falls ill on a heatable brick bed, it is impossible to move, and left hand and some consciousness of arms and legs do not have yet, and speak not clear, and then 2015
Start oral this pharmaceutical composition (embodiment 1 pharmaceutical composition lot number 20121229) treatment on February 28, in, three times a day, every time
1.5g, can be with Go to ground activity after serveing on 2 months, communication that can be more visible with people, and the check of 4 Ge Yuehou hospitals, blood pressure is normal, raw
Live normal, after continue to take and thoroughly cure for 2 months.
Claims (8)
1. the pharmaceutical composition treating cerebral thrombosis, it is characterised in that make composition and the weight of the crude drug of this pharmaceutical composition
Amount part is:
Calendula arvensis L. 650-750g, Herba thymi vulgaris 2450-2550g, Fructus Nandinae Domesticae 2650-2750g, smelly arrow dish 3250-3350g, Blatta seu periplaneta
4650-4750g, protopine 102-112g, 19-deoxidation-15-chlorine Jia Shi cyanidin 93-103g.
A kind of pharmaceutical composition treating cerebral thrombosis, it is characterised in that make this pharmaceutical composition
The composition of crude drug and weight portion be:
Calendula arvensis L. 700g, Herba thymi vulgaris 2500g, Fructus Nandinae Domesticae 2700g, smelly arrow dish 3300g, Blatta seu periplaneta 4700g, protopine 107g, 19-
Deoxidation-15-chlorine Jia Shi cyanidin 98g.
A kind of pharmaceutical composition treating cerebral thrombosis, it is characterised in that pharmaceutical composition can be adopted
It is prepared as tablet or capsule or drop pill by the conventional method of galenic pharmacy.
A kind of pharmaceutical composition treating cerebral thrombosis, it is characterised in that pharmaceutical composition and chemistry
Medicine or the treatment cerebral thrombosis medicine of Chinese medicine composition.
5. the preparation method of the pharmaceutical composition treating cerebral thrombosis, it is characterised in that prepare as follows:
The composition of crude drug and weight portion be: Calendula arvensis L. 650-750g, Herba thymi vulgaris 2450-2550g, Fructus Nandinae Domesticae 2650-2750g,
Smelly arrow dish 3250-3350g, Blatta seu periplaneta 4650-4750g, protopine 102-112g, 19-deoxidation-15-chlorine Jia Shi cyanidin 93-
103g；
Preparation method:
(1) Calendula arvensis L., Herba thymi vulgaris, Fructus Nandinae Domesticae, smelly arrow dish, Blatta seu periplaneta, protopine, 19-deoxidation-15-chlorine are taken by crude drug proportioning
Jia Shi cyanidin, mixing, with weight percent concentration 46.5% ethanol as solvent, extract at 57 DEG C of warm macerating, extraction time is
8 times, each extraction time is 30 hours, and each solvent load is 45 times of crude drug gross weight, filters, obtains medicinal residues A and extraction
Liquid A, extracting solution A reclaim ethanol, are concentrated into relative density 1.12, filter, and medicinal liquid passes through LSA-40 macroporous adsorptive resins, first uses
Water elution, then with weight percent concentration 63% ethanol solution eluting LSA-40 macroporous adsorptive resins, collect percentage by weight dense
Spend 63% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A；
(2) take step (1) medicinal residues A, with weight percent concentration 41% ethanol as solvent, heating and refluxing extraction 11 times, carry every time
The time of taking is 1.5 hours, and each solvent load is 15 times of medicinal residues A weight, filters, obtains medicinal residues B and extracting solution B, and extracting solution B returns
Receiving ethanol, be concentrated into relative density 1.14, filter, medicinal liquid passes through DM11 macroporous adsorptive resins, first washes with water, then uses weight
Percent concentration 64% ethanol solution eluting DM11 macroporous adsorptive resins, collects weight percent concentration 64% ethanol elution,
Reclaim ethanol, concentrate drying, obtain extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
The preparation method of a kind of pharmaceutical composition treating cerebral thrombosis, it is characterised in that by as follows
Prepared by step:
The composition of crude drug and weight portion be: Calendula arvensis L. 700g, Herba thymi vulgaris 2500g, Fructus Nandinae Domesticae 2700g, smelly arrow dish 3300g, roach
Dung beetle 4700g, protopine 107g, 19-deoxidation-15-chlorine Jia Shi cyanidin 98g；
Preparation method:
(1) Calendula arvensis L., Herba thymi vulgaris, Fructus Nandinae Domesticae, smelly arrow dish, Blatta seu periplaneta, protopine, 19-deoxidation-15-chlorine are taken by crude drug proportioning
Jia Shi cyanidin, mixing, with weight percent concentration 46.5% ethanol as solvent, extract at 57 DEG C of warm macerating, extraction time is
8 times, each extraction time is 30 hours, and each solvent load is 45 times of crude drug gross weight, filters, obtains medicinal residues A and extraction
Liquid A, extracting solution A reclaim ethanol, are concentrated into relative density 1.12, filter, and medicinal liquid passes through LSA-40 macroporous adsorptive resins, first uses
Water elution, then with weight percent concentration 63% ethanol solution eluting LSA-40 macroporous adsorptive resins, collect percentage by weight dense
Spend 63% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A；
(2) take step (1) medicinal residues A, with weight percent concentration 41% ethanol as solvent, heating and refluxing extraction 11 times, carry every time
The time of taking is 1.5 hours, and each solvent load is 15 times of medicinal residues A weight, filters, obtains medicinal residues B and extracting solution B, and extracting solution B returns
Receiving ethanol, be concentrated into relative density 1.14, filter, medicinal liquid passes through DM11 macroporous adsorptive resins, first washes with water, then uses weight
Percent concentration 64% ethanol solution eluting DM11 macroporous adsorptive resins, collects weight percent concentration 64% ethanol elution,
Reclaim ethanol, concentrate drying, obtain extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
The preparation method of a kind of pharmaceutical composition treating cerebral thrombosis, it is characterised in that medicine group
Compound can use the conventional method of galenic pharmacy to be prepared as tablet or capsule or drop pill.
The preparation method of a kind of pharmaceutical composition treating cerebral thrombosis, it is characterised in that medicine group
Compound and chemical drugs or Chinese medicine composition treatment cerebral thrombosis medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610515685.2A CN106109564A (en) | 2016-07-04 | 2016-07-04 | Pharmaceutical composition for the treatment of cerebral thrombosis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610515685.2A CN106109564A (en) | 2016-07-04 | 2016-07-04 | Pharmaceutical composition for the treatment of cerebral thrombosis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106109564A true CN106109564A (en) | 2016-11-16 |
Family
ID=57469112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610515685.2A Withdrawn CN106109564A (en) | 2016-07-04 | 2016-07-04 | Pharmaceutical composition for the treatment of cerebral thrombosis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106109564A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106581482A (en) * | 2016-12-10 | 2017-04-26 | 济南昊雨青田医药技术有限公司 | Medicinal composition for treating pyelonephritis, and preparation method thereof |
| CN106727878A (en) * | 2016-12-10 | 2017-05-31 | 济南昊雨青田医药技术有限公司 | It is a kind of to treat pharmaceutical composition of cerebral thrombus and preparation method thereof |
| CN109125355A (en) * | 2018-08-03 | 2019-01-04 | 昆明医科大学第附属医院 | The grand antiplatelet of heart arteries and veins and antithrombotic pharmacology action |
-
2016
- 2016-07-04 CN CN201610515685.2A patent/CN106109564A/en not_active Withdrawn
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106581482A (en) * | 2016-12-10 | 2017-04-26 | 济南昊雨青田医药技术有限公司 | Medicinal composition for treating pyelonephritis, and preparation method thereof |
| CN106727878A (en) * | 2016-12-10 | 2017-05-31 | 济南昊雨青田医药技术有限公司 | It is a kind of to treat pharmaceutical composition of cerebral thrombus and preparation method thereof |
| CN109125355A (en) * | 2018-08-03 | 2019-01-04 | 昆明医科大学第附属医院 | The grand antiplatelet of heart arteries and veins and antithrombotic pharmacology action |
| CN109125355B (en) * | 2018-08-03 | 2022-07-08 | 昆明医科大学第一附属医院 | Psychopharmacology application of Xinmailong for anti-platelet and anti-thrombus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102139030B (en) | Oral Chinese herbal preparation for treating gingivitis and preparation method thereof | |
| CN106109564A (en) | Pharmaceutical composition for the treatment of cerebral thrombosis and preparation method thereof | |
| CN104435487A (en) | Traditional Chinese medicine for treating hypertension complicated with diabetic fundi disease and preparation method thereof | |
| CN103845616A (en) | Pharmaceutical composition for eliminating inflammation and disinfecting | |
| CN105031329A (en) | Traditional Chinese medicine preparation used for treating liver qi stagnation-type hemicranias, and preparation method thereof | |
| CN102274330B (en) | Medicament for treating beriberi | |
| CN106581357A (en) | Pharmaceutical composition for treatment of recurrent oral ulcer | |
| CN106668240A (en) | Pharmaceutical composition for treating vitreous opacity | |
| CN106109927A (en) | A kind of pharmaceutical composition treating chloasma and preparation method thereof | |
| CN105596590A (en) | Traditional Chinese medicine preparation for treating herpes labialis and preparation method thereof | |
| CN105596929A (en) | Preparing method for traditional Chinese medicine preparation for treating phlegm-heat excessive accumulation type chronic cough | |
| CN105031065A (en) | Traditional Chinese medicine for treating acute suppurative otitis media and preparation method of traditional Chinese medicine | |
| CN104352974A (en) | Ciliatenerve knotweed root-containing traditional Chinese medicine composition for treating diabetes | |
| CN105395914A (en) | Traditional Chinese medicine composition for treating cystolith and preparation method and application thereof | |
| CN103550284A (en) | Traditional Chinese medicine composition for treating urinary calculus and preparation method thereof | |
| CN106581263A (en) | Pharmaceutical composition for treating lumbar disc herniation and preparation method thereof | |
| CN106692503A (en) | Pharmaceutical composition for prevention and treatment of tuberculosis and preparing method thereof | |
| CN102940671A (en) | Medicine composition for treating diabetic foot | |
| CN105832901A (en) | Traditional Chinese medicine preparation for treating acute pancreatitis and preparation method thereof | |
| CN106729032A (en) | Pharmaceutical composition for treating cold in children | |
| CN106728625A (en) | A kind of pharmaceutical composition for treating rhinitis | |
| CN107468920A (en) | A kind of Chinese medicine preparation for treating blood transfusion hemolytic reaction | |
| CN106729025A (en) | Prevent and treat pharmaceutical composition of cold in children and preparation method thereof | |
| CN106668288A (en) | Pharmaceutical composition for treating recurrent oral ulceration | |
| CN106581326A (en) | Pharmaceutical composition for preventing and treating senile osteoporosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20161116 |
|
| WW01 | Invention patent application withdrawn after publication |